The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study
Open accessAbstract
PURPOSE: To describe the clinical and pathologic characteristics of a case of retinal vasculitis and vitritis following brolucizumab administration and subsequent ranibizumab treatment. OBSERVATIONS: A 76-year old Caucasian woman experienced pain, decreased vision and floaters one week after receiving her third monthly intravitreal brolucizumab injection in the right eye for exudative age-related macular degeneration. Examination was significant for 0.5+ anterior chamber cells, vitritis, mild peripheral vascular sheathing, and decreased vision from 20/70 to 20/200. She was started on topical 1% prednisolone acetate with improvement in her examination. She was switched to ranibizumab one month after her last brolucizumab injection of the right eye. Three weeks after her ranibizumab injection, she noticed photophobia, pain and decreased vision. Examination revealed worsening uveitis, vitritis, vascular sheathing, and decreased vision to count fingers. Despite starting on 0.05% difluprednate drops every 2 hours and oral high-dose methylprednisolone, the patient did not have any significant improvement in her symptoms or examination. She underwent pars plana vitrectomy and vitreous biopsy with intravitreal triamcinolone injection to the right eye. Vitreous biopsy and culture ruled out infectious endophthalmitis, and further cytopathologic analysis revealed chronic inflammatory infiltrate. CONCLUSION AND IMPORTANCE: Treatment with brolucizumab can result in intraocular inflammation and retinal vasculitis likely due to a delayed hypersensitivity reaction to the drug, supported by cytopathologic analysis of a vitreous sample. We demonstrate a case where retreatment with an alternative anti-VEGF agent resulted in worsening vision and vasculitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be a factor as to why increased IOI was observed with brolucizumab, as the EMA did find a correlation found to incidence of intraocular inflammation and elevated titers of ADA in clinical trials with brolucizumab [38, 41, 42].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent case report analyzing a vitreous sample obtained during vitrectomy of a patient with brolucizumab-related retinal vasculitis showed the presence of CD3, CD4, CD8, and CD68.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“However, the presence of both B and T cells may indicate a mixed type III and IV reaction [42].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“These findings indicate the presence of T cells and histocytes, favoring a type IV reaction [42].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
The Clinical Aspects of Immunology.
(1964) · Annals of Internal Medicine · doi:10.7326/0003-4819-60-2-339_1 · Cited by 705
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
Baumal, C. R., Spaide, R. F., Vajzovic, L., Freund, K. B., Walter, S. D., John, V., Rich, R., Chaudhry, N., Lakhanpal, R. R., Oellers, P. R., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.017 · Cited by 312
Self-citationThe classification of allergic reactions underlying disease
Pgh, G. (1963) · Medical Entomology and Zoology · Cited by 279
Dugel, P. U., Jaffe, G. J., Sallstig, P., Warburton, J., Weichselberger, A., Wieland, M., & Singerman, L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.057 · Cited by 236
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Kuriakose, A., Chirmule, N., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 227
Immunopathogenesis of delayed‐type hypersensitivity
Kobayashi, K., Kaneda, K., & Kasama, T. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1090 · Cited by 222
Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis
Witkin, A. J., Chang, D. F., Jumper, J. M., Charles, S., Eliott, D., Hoffman, R. S., Mamalis, N., Miller, K. M., & Wykoff, C. C. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.11.042 · Cited by 176
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
Haug, S. J., Hien, D. L., Uludag, G., Ngoc, T. T. T., Lajevardi, S., Halim, M. S., Sepah, Y. J., Do, D. V., & Khanani, A. M. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100680 · Cited by 142
Research works printed but not linked: 1
- Novartis. Novartis Provides Update on Use and Safety of Beovu (Brolucizumab). April vol. 28, 2020.
Cited by
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Mukai, R., Matsumoto, H., & Akiyama, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259879 · Cited by 54
Holz, F. G., Iida, T., Maruko, I., & Sadda, S. R. (2022) · Retina · doi:10.1097/iae.0000000000003556 · Cited by 49
Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy
Tomkins‐Netzer, O., Niederer, R. L., Greenwood, J., Fabian, I. D., Serlin, Y., Friedman, A., & Lightman, S. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101245 · Cited by 46
Wykoff, C. C., Matsumoto, H., Barakat, M., Karcher, H., Lozama, A., Mayhook, A., Oshagbemi, O. A., Zorina, O., Hassan, T., Khanani, A. M., et al. (2023) · Retina · doi:10.1097/iae.0000000000003769 · Cited by 40
Metadata
- Authors
- Iyer, P. G., Peden, M. C., Suñer, I. J., Patel, N., Dubovy, S. R., & Albini, T. A.
- Affiliations
- Retina Associates of Florida (US)
- Corresponding author
- Albini, Thomas A.
- Venue
- American Journal of Ophthalmology Case Reports
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 20
- Pages
- 100989
- ISSN
- 2451-9936 (ISSN-L)
- PMC
- PMC7695942
- OpenAlex
- W3101908837
- Cited by
- 60
- References
- 25
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 16 · 2023: 8 · 2022: 11 · 2021: 17
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Locations
- American Journal of Ophthalmology Case Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Minnesota Lions Eye Bank
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- brolucizumab, ranibizumab, retinal vasculitis, vitritis, uveitis, anti-VEGF therapy adverse effects, drug hypersensitivity, neovascular age-related macular degeneration, vitreous biopsy, vitrectomy, intravitreal triamcinolone acetonide, corticosteroid therapy, retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. https://app.cochat.ai/papers/10.1016/j.ajoc.2020.100989
- The paper
- Iyer, P. G., Peden, M. C., Suñer, I. J., Patel, N., Dubovy, S. R., & Albini, T. A. (2020). Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. American Journal of Ophthalmology Case Reports. https://doi.org/10.1016/j.ajoc.2020.100989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.